Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 trial of multidose vial 13-valent pneumococcal conjugate vaccine in healthy infants
2012-000482-21Phase 3
- Sponsor
- Pfizer
- Start
- Feb 2015
- Modality
- Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of pneumococcal 13-valent conjugate vaccine in pneumococcal disease (2 arms), sponsored by Pfizer. Primary endpoint: Serotype-specific IgG responder rate after infant series.
02
Drugs
pneumococcal 13-valent conjugate vaccine
03
Conditions
pneumococcal disease
Beyond the preview
Go deeper on 2012-000482-21.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2012-000482-21.